CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies

Inclusion Criteria: * Patients with relapsed / refractory previously treated B cell malignancies (according to the World Health Organization classification; 2017) * Patients must have received adequate prior therapy including at least two lines of prior therapies including anthracycline or bendamustine-containing chemotherapy, anti-CD20 (cluster of differentiation antigen 20) therapies and/or Brutton's tyrosine kinase (BTK) inhibitors * Patients treated with prior CD19 targeted molecules (e.g., Blincyto) must have confirmed CD19+ disease * Patients must be ineligible for allogeneic stem cell transplant (SCT) * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1 * Estimated life expectancy of ≥ 12 weeks from the first day of SWI019 dose administered * Willing to undergo pre- and post-treatment core needle biopsy * Adequate hematological, renal, pulmonary, cardiac, and liver function * Resolved adverse events of any prior therapy to either baseline or CTCAE Grade ≤1 * Women of childbearing potential, a negative pregnancy test and must agree to practice effective birth control * Men sexually active with female partners of child bearing potential must agree to practice effective contraception * Willing and able to comply with scheduled visits, treatment plan, laboratory tests and other procedures Exclusion Criteria: * Patients diagnosed with certain disease histologies including pediatric lymphomas/leukemias, monoclonal gammopathy of undetermined significance (MGUS), T-cell histiocyte large B cell lymphoma * Pregnant or lactating women * Active bacterial, viral, and fungal infections * History of allogeneic stem cell transplantation * Treatment with any prior lentiviral or retroviral based CAR-T * Patients receiving live (attenuated) vaccines within 4 weeks of screening visit or need for live vaccine on study * Patients with known active central nervous system (CNS) disease. Patients with prior CNS disease that has been effectively treated may be eligible * History of Class III or IV New York Heart Association (NYHA) heart failure, myocardial infarction, unstable angina or other significant cardiac disease within 6 months of screening * Involvement of cardiac tissue by lymphoma * Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura (ITP) * HIV-1 and HIV-2 antibody positive patients